Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients

Figures & data

Table I. Description of general patient characteristics, site of primary tumor, adrenal metastases and treatment characteristics.

Patient characteristics (n = 34)
Gender: Male/Female (n; %)	30/4	88%/12%
Age (median; range)	67	27–86
Site of primary
NSCLC (n; %)	22	64%
SCLC	3	7%
Melanoma	3	7%
Esophagus	1	7%
Hepatic duct adenocarcinoma	1	3%
Lung sarcoma	1	3%
Colorectal adenocarcinoma	1	3%
Renal cell carcinoma	1	3%
unknown	1	3%
Adrenal metastases
Monolateral involvement (n; %)	5	14.7%
Metastasis site (right/left)	19/17	52%/47%
Treatment characteristics (n = 36)
Dose (median; range)	32	20–45
Fractions (median; range)	4	4–18

Figure 1. Kaplan-Meier curve describing local progression.

Figure 2. Kaplan-Meier curve describing progression free survival and overall survival.

Table II. Description and comparison of the main characteristics of the studies published on this subject.

Study	Number of patients	Median dose and number of fractions (fr.)	Median follow-up (months)	Local control rate	Overall survival	Toxicity
Casamassima et al. [21]	48	36 Gy/3 fr.	16.2 (3–63)	90% (at 1–2 years)	39.7% (at 1 year) 14.5% (at 2 years)	1 case of grade II adrenal insufficiency
Chawla et al. [17]	30	40 Gy/10 fr.	9.8 (3.2–28.3)	55% (at 1 year)	44% (at 1 year) 25% (at 2 years)	mild fatigue/nausea grade 1 were “common”
Oshiro et al. [18]	19	45 Gy/10 fr.	11.5 months (5.4–87.8 months)	68% (objective response rate)	56% (at 1 year) 33% (at 2 years) 22% (at 3 years)	1 grade 2 duodenal ulcer
Holy et al.[19]	18	20 Gy/5 fr. or40 Gy/8fr.	21	77% (objective response rate)	23 months (median)	-
Torok et al. [20]	7	16 Gy/1 fr. or27/3 fr.	14 (1–60)	63% (at 1 year)	8 months (median)	-

Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys Epub 2011 Feb 5.

 Google Scholar

Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, . Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009;75:71–5.

 PubMed Web of Science ®Google Scholar

Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 2011;34:249–53.

 PubMed Web of Science ®Google Scholar

Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245–51.

 PubMed Web of Science ®Google Scholar

Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: A retrospective review of a noninvasive therapeutic strategy. Future Oncol 2011;7:145–51.

 PubMedGoogle Scholar